Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 05/27 05:30:02 pm
79.6 CHF   +0.32%
05/27 Novartis, Foundation Medicine, Celgene Invest in Healthcare Infor..
05/27 CATALENT : Strengthens Leadership Position in Asia-Pacific with Key ..
05/26 Anacor received rival bid before Pfizer deal - filing
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
05/23/2016 05/24/2016 05/25/2016 05/26/2016 05/27/2016 Date
77(c) 77.85(c) 78.9(c) 79.35(c) 79.6(c) Last
7 679 701 5 776 931 6 528 605 7 130 147 4 469 939 Volume
+2.60% +1.10% +1.35% +0.57% +0.32% Change
More quotes
Financials ($)
Sales 2016 48 879 M
EBIT 2016 12 640 M
Net income 2016 7 583 M
Debt 2016 14 260 M
Yield 2016 3,54%
Sales 2017 50 401 M
EBIT 2017 13 633 M
Net income 2017 8 887 M
Debt 2017 12 176 M
Yield 2017 3,74%
P/E ratio 2016 22,69
P/E ratio 2017 20,34
EV / Sales 2016 4,62x
EV / Sales 2017 4,44x
Capitalization 211 487 M
More Financials
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, Vaccines & Diagnostics, and Consumer Health.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers surgical,... 
Sector
Pharmaceuticals
Calendar
06/04 | 03:00pmPresentation
More about the company
Surperformance© ratings of Novartis AG
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS AG
05/27 Novartis, Foundation Medicine, Celgene Invest in Healthcare Informatics Firm ..
05/27 CATALENT : Strengthens Leadership Position in Asia-Pacific with Key Appointments..
05/26 Anacor received rival bid before Pfizer deal - filing
05/26 CATALENT : Strengthens Leadership Position in Asia-Pacific with Key Appointments..
05/26 NOVARTIS : Creating the sights and sounds
05/25 NOVARTIS : highlights its strong foundation for long-term, sustainable growth at..
05/25 NOVARTIS : highlights its strong foundation for long-term, sustainable growth at..
05/24 NOVARTIS : Sandoz' biosimilar rituximab regulatory submission accepted by Europe..
05/23DJSAMSUNG ELECTRONICS : Targets U.S. Drug Market With Remicade Knockoff
05/23 NOVARTIS' : Entresto given strong Class I recommendation in both US and EU heart..
More news
Sector news : Pharmaceuticals - NEC
03:10p JOHNSON & JOHNSON : Telling the stories of a son fallen in combat, and also vete..
05/28 SUN PHARMACEUTICAL : Pharma Q4 profit seen up 113%, Gleevec may drive US sales
05/28 TAKEDA PHARMACEUTICAL : Receives Positive CHMP Opinion for ADCETRIS (brentuximab..
05/28DJSUBSCRIBERS : Covestro News Reported in April
05/28DJCovestro Eyes Acquisitions, Says Finance Chief - Report
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/26 THE GOOD BUSINESS PORTFOLIO : 2016 1st-Quarter Earnings And Performance Review
05/25 Gain 50% From This Bidding War, Part II
05/24 PDL Bio acquires anti-hypertension drugs from Novartis for up to $145M
05/24 At Last Some Good News For Entresto
05/24 In-House Projects An Ever-Thinner Slice Of Sales For Big Pharma
Advertisement
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions